Lawrence F Eichenfield, Eric L Simpson, Kim Papp, Jacek C Szepietowski, Andrew Blauvelt, Leon Kircik, Jonathan I Silverberg, Elaine C Siegfried, Michael E Kuligowski, May E Venturanza, Howard Kallender, Haobo Ren, Amy S Paller
BACKGROUND: Atopic dermatitis (AD), a highly pruritic, inflammatory skin disease, affects approximately 7% of adolescents globally. A topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor, demonstrated safety and efficacy among adolescents/adults in two phase 3 studies (TRuE-AD1/TRuE-AD2). OBJECTIVE: To describe safety and efficacy of 1.5% ruxolitinib cream versus vehicle and long-term disease control of ruxolitinib cream among adolescents aged 12-17 years from pooled phase 3 study data...
May 2, 2024: American Journal of Clinical Dermatology